EW INSIGHTS into the pathogenesis of lymphoid ma-N lignancies have been gained by novel techniques such as genetic, molecular, and immunologic methods and have not only broadened our knowledge about the origin and development of malignant lymphomas, but also have substantial clinical implications. Hence, distinct disorders can be defined more precisely and therapeutic strategies may be directed more specifically to well-defined lymphoma entities. The closing gap between a better understanding of lymphoma biology and its translation into the clinical management of lymphoid malignancies requires an appropriate adaptation of histopathologic classification and clinical grouping and stimulates the reflection and reassessment of previously developed and newly proposed classification systems.
Over the past 40 years, the challenge of adaptation to new knowledge and novel techniques has reappeared several times and has prompted reconsideration of the classification and clinical grouping of malignant lymphomas from time to time. The process of reconsideration has regularly followed a sequence of steps which comprise the proposal of a new classification, its evaluation and testing, its acceptance and broad application or rejection, respectively, and finally its revision and modification as new information is gained (Fig   1) .
Two years ago, a new histopathologic classification for neoplasms of the lymphoid lineage was proposed by the International Lymphoma Study Group.' It emerged from the joint efforts of an international group of pathologists who tried to adapt the categorization of malignant lymphomas to the present status of knowledge and techniques. The first step of a new classification system was, therefore, signaled by the appearance of the "Revised European American Lymphoma" schema which has now entered the subsequent stages of evaluation and testing.' At the second anniversary of its publication in Blood, it seems appropriate to consider the general concept of the "Revised European American Lymphoma' ' classification, its potential clinical application and perspective, as well as its differences from preceeding groupings.
THE DEVELOPMENT OF CLASSIFICATION SYSTEMS
The first, broadly applied classifications of lymphoid neoplasms, such as the one introduced by Rappap~rt,~ were based on histologic and cytologic characteristics of lymphoma cells and were mainly descriptive. Stimulated by the expanding knowledge about the physiology of the lymphatic system, the subsequently introduced Kiel and Lukes and Collins classifications took another approach and attempted to relate the malignant lymphomas to their normal counterparts within the lymphatic system from which they might have emerged!d A different way was chosen to generate the Working Formulation, which was predominantly based on clinical parameters and hematoxilideosin (H&E) morphology, grouping the lymphomas according to their natural history, their response to therapy, and their overall survival. ' Within the last decade, we have experienced the establishment of immunophenotyping as one of our diagnostic tools and the increasing use of molecular biologic and genetic techniques that are, however, not yet accepted as mandatory elements of diagnostic assessments. These developments not only open a new way to understand the biology of malignant lymphomas but have even served to identify previously unrecognized entities with distinct histopathological and clinical features. One example illustrating this achievement is mantle cell lymphoma which, despite its inclusion as centrocytic lymphoma in the Kiel classification, was not generally accepted as a separate histologic or clinical entity until the detection of the characteristic translocation t ( 11; 14) . By this genetic event the cyclin D 1 gene is juxtaposed to the Ig heavy-chain gene and results in the overexpression of cyclin D 1 and possibly the deregulation of the cell cycle. This knowledge provided the means to further define the histologic and immunophenotypic characteristics of mantle cell lymphoma and to recognize it as a distinct This clarification also translated into a better assessment of the clinical features and prognosis of mantle cell lymphomas and confirmed the previously described poor therapeutic outcome.lo." Similar disease-associated genetic and molecular aberrations have been recognized for many of the lymphoid The rapidly expanding knowledge about the pathophysiology of malignant lymphomas provides the perspective to translate these findings into a more biologically oriented classification of these disorders and to adapt the categorization of malignant lymphomas to the current knowledge and diagnostic techniques. The "Revised European American Lymphoma Classification" that emerged after more than 3 years of intensive discussions and exchange of opinions among expert pathologists can be considered a most comprehensive summary of known entities and an important next step toward a more biologically oriented grouping of malignant lymphomas. Therefore, it appears as a logical consequence within the historical development of efforts to classify malignant lymphomas and is by itself certainly not intended to mark a final endpoint.
THE PURPOSE OF CLASSIFICATIONS
When considering the different classification systems that have been applied over the years, they all try to fulfill two major needs. They must allow the definition of a distinct lymphoma subgroup and thus establish a proper diagnosis. 
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For personal use only. on April 14, 2017. by guest www.bloodjournal.org From At the same time they must be clinically useful and enable clinicians to estimate the prognostic relevance of this diagnosis and to guide therapeutic decisions accordingly. At the second anniversary of the publication of the "Revised European American Lymphoma" classification, it seems appropriate to ask whether and how these needs are fulfilled by the new proposal and whether and how it may improve upon the two major classifications that are currently in use, the Working Formulation and the Kiel classification, respectively. As mentioned before, the Working Formulation is a clinically oriented schema that emerged from the analysis of the clinical course and survival of patients undergoing lymphoma therapy in the late 1960s and early 1970s. This approach is relatively simple and has met great acceptance, especially in the United States. It also has served as the basis for numerous clinical trials.
Given the new insights into lymphoma biology that have identified important new subgroups not distinguished previously, it must be questioned whether this grouping system is still appropriate. Hence, several groups have already modified the Working Formulation to meet their current needs and have incorporated new entities such as the mantle cell lymphoma or the mucosa-associated lymphoid tissue (MALT) lymphoma, to name only two examples. Similarly, the G e l classification has adapted new developments and was updated recently.I4 It never lost, however, its main foundation resting on the postulated relationship of neoplastic lymphoma cells to their normal counterparts in the immune system. This biologically oriented approach makes it understandable that the new "Revised European American Lymphoma" proposal corresponds in many aspects to the Kiel scheme. However, it also tries to correct for some of the Kiel schema's limitations. Hence, it makes no attempt to divide the non-Hodgkin's lymphomas (NHLs) into high-and low-risk categories on the basis of cell morphology alone. It also does not subdivide the large B-cell lymphomas into different entities given the current lack of information about clinically important distinctions and of histopathologic reproducibility. Furthermore, the ' 'Revised European American Lymphoma" classification includes lymphomas at all sites and thus encompasses the extranodal lymphomas, including those of the gastrointestinal tract, which were not covered by the Kiel system. Tables 1 and 2 illustrate the tentative interrelations of the ''Revised European American Lymphoma" scheme with the Kiel classification and the Working Formulation for NHLs of the B-and T-cell lineages as initially described by Harris et al.' These relationships must be considered as approximations only and cannot be complete. In the respective classification systems several entities are not recognized or are defined differently and thus correspond to each other only in part. Furthermore, a single entity in the "Revised European American Lymphoma" classification, such as mantle cell lymphoma, may be placed in four or five of the Working Formulation categories.
When pointing out the limitations of the Working Formulation and the Kiel classification, it should not be overlooked that both systems were readily accepted by clinicians and were broadly applied. The clinical appreciation and acceptance was certainly facilitated by the close association of histopathologic entities with the clinical categories of low-, intermediate-, and high-grade lymphomas, which provided a gross prediction of natural history and clinical course and served as guidance for therapeutic decisions. The "Revised European American Lymphoma" proposal lacks the translation into clinical groupings and hence deserves a further For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From interpretation to facilitate its acceptance and clinical applicability." This translation is also warranted to ease the adaptation of clinicians from an easily understandable but biologically incomplete and clinically insufficient classification such as the Working Formulation to a more complex but biologically and clinically more accurate system. Taking into account that the "Revised European American Lymphoma" schema does not create new entities but rather summarizes accepted and recognizable diseases, its translation into prognostically and therapeutically relevant categories can be done with little difficulty.
A CLINICAL GROUPING OF ENTITIES ACCORDING TO THE "REVISED EUROPEAN AMERICAN LYMPHOMA CLASSIFICATION"
To facilitate the translation of the "Revised European American Lymphoma" classification into a clinically useful grouping and to reach a broad international consensus, a series of formal and informal meetings among clinicians and pathologists have taken place since early 1994, the most recent one being held at the VIth Intemational Conference on Malignant Lymphomas at Lugano, Switzerland. From these discussions, and supported by two large retrospective studies evaluating the clinical meaning of the REAL schema which will be published shortly, a clinical grouping schema was developed. It follows the major distinction of the REAL classification into lymphomas of B-and T-cell lineage. Within each lineage three categories of disorders are defined: I Indolent (Low-Risk) Lymphomas; I1 Aggressive Lymphomas (Intermediate-Risk), and I11 Very Aggressive Lymphomas (High-Risk). Hodgkin's Disease is listed as a further category ( Table 3) .
The definition of these categories is based on the clinical course of the respective entities and the results that can be expected from presently available treatment modalities. The clinical grouping is meant to serve as a gross orientation only and does not imply that one should approach the listed entities by uniform treatment strategies. Rather, specific therapies must be applied to distinct entities whenever available.
Nevertheless, some common features are shared by a variety of different lymphomas that allow them to be grouped into the designated categories. Hence, indolent lymphomas are mostly diagnosed at advanced stages 111 and IV and are characterized by a slowly progressive clinical course during which spontaneous regression may be observed. Sensitivity to chemotherapy is moderate and final disease eradication For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From and cure is rarely achievable by currently available cytostatic regimens. Aggressive lymphomas, on the other hand, have a more rapid clinical course, a moderate to good response to chemotherapy and a considerable proportion of patients experience long-term disease-free and overall survival after antineoplastic treatment. The very aggressive lymphomas show even more rapidly expanding growth characteristics and usually constitute an imminent life-threatening situation to the patient. In most of the latter disorders effective therapy is, however, available and can be applied with a significant chance for cure.
Although the delineation of most histopathologically defined lymphoma entities into these clinical categories appears straightforward and is supported by appropriate clinical data, the grouping of other, more recently defined subgroups still deserves further assessment by controlled clinical trials. As a first step, an international project has been carried out that aims to evaluate the applicability of the "Revised European American Lymphoma" classification and the clinical grouping at 10 major centers around the world. This major effort is expected to provide further data about the clinical course of certain lymphoma subtypes that will allow their appropriate designation within the proposed clinical grouping. To take these open questions into account, but at the same time provide tentative guidelines for clinicians and familiarize them with the new classification, the respective entities are marked as provisionally grouped categories in Table 3 .
FUTURE PERSPECTIVES
The proposed grouping of clinically and histopathologically defined lymphoma entities includes the basic determinants of morphology and clinical course and will serve both pathologists and clinicians to reach a widely acceptable basis for further improvements in the diagnosis and management of malignant lymphomas. Indeed, an ongoing World Health Organization project on lymphoma classification is already building on these prerequisites. Therefore, the "Revised European American Lymphoma" classification and the accompanying clinical grouping may provide an internationally agreed upon approach which by way of a joint venture will help to close the gap between the protagonists of the two major currently used classification systems, the Working Formulation and the Kiel classification. Overall, these activities and the intensive debates and discussions during the last few years emphasize the willingness to join efforts and it is hoped that new understandings emerging from these international collaborations translate into meaningful benefits for patients suffering from lymphoid malignancies.
